Peptides are not a checkout protocol

The rule before any peptide

Peptides are not one clean consumer category. The same word covers approved prescription medicines, investigational obesity drugs, pharmacy-compounded substances, gray-market injectables, topical cosmetic ingredients and oral collagen supplements. Scoring them as if they were red light panels or trackers would be fake precision.

For now, Agewell gives no individual advice on whether to use a peptide, which peptide to use, dosing, cycling or stacking. The only defensible consumer screen is process: a named prescriber, a real indication or objective, a lawful source, a named pharmacy, baseline labs where relevant, monitoring, an adverse-event plan and written stop criteria. Vials sold as research-use-only are a walk-away signal.

Metabolic peptides: semaglutide, tirzepatide and retatrutide

Semaglutide and tirzepatide are the evidence-heavy end of the peptide conversation. They are prescription metabolic medicines, not casual longevity add-ons. Wegovy and Zepbound carry FDA-approved indications for weight management in defined patients, and their labels also carry contraindications, boxed warnings and monitoring issues that belong with a clinician, not a checkout flow.

Retatrutide, often shortened online to “reta”, is different. It is Lilly’s investigational triple agonist targeting GIP, GLP-1 and glucagon receptors. Phase 3 results are strong enough that everyone in longevity is watching it, but it is not FDA-approved as of this update and Lilly says it is legally available only inside clinical trials. Anything sold as retatrutide by a medspa, online vendor or research-chemical site should be treated as unverified.

Injury and repair peptides: BPC-157 and TB-500

BPC-157 is the famous “healing peptide” in biohacker and training circles, usually marketed for tendon, ligament, gut or injury recovery. The consumer story is far ahead of the clinical file. FDA has flagged compounded BPC-157 for limited safety information, immunogenicity concerns and peptide-impurity/API-characterization complexity. That does not prove harm in every case; it means Agewell cannot treat it as a normal recommendation.

TB-500 is the common name attached to a thymosin beta-4 fragment. It is sold for recovery, soft-tissue repair and performance, but FDA says it has not identified human exposure data for compounded products containing that fragment and lacks enough information to know whether it would cause harm. For tested athletes, many growth-factor and peptide-hormone categories also create anti-doping risk.

Growth-hormone-axis peptides

CJC-1295, ipamorelin and sermorelin are usually pitched as ways to increase growth-hormone signaling without taking growth hormone directly. That is still a medical axis, not a wellness menu. FDA has flagged CJC-1295 and ipamorelin in the compounding-risk context, including limited clinical data, impurity concerns and serious adverse-event signals described in its peptide table.

Tesamorelin is the important distinction. It is an FDA-approved growth-hormone-releasing factor analog for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label is explicit that it is not indicated for general weight-loss management, and it brings issues such as IGF-1 monitoring, glucose effects and malignancy screening. That is the level of specificity clinics should be held to.

Fat-loss, mitochondrial and anti-aging peptides

AOD-9604 is marketed as a fat-loss peptide, but FDA has flagged compounded AOD-9604 for immunogenicity and impurity concerns, limited safety information and serious adverse events where causality is not clear. AOD-9604 is exactly the kind of peptide where marketing can sound simple while the regulatory and safety picture is not.

MOTS-c and SS-31/elamipretide sit in the mitochondrial-peptide lane. The idea is attractive: target cellular energy and resilience. The consumer market, however, is far ahead of approved use. FDA lists MOTS-c among peptide substances with limited or absent human exposure information for compounded use. Elamipretide has been studied clinically, but that does not make gray-market mitochondrial stacks a consumer protocol.

Epitalon, DSIP/emideltide, Selank and Semax show up in anti-aging, sleep, anxiety and focus discussions. Regulatory status varies by country, and the US compounding-risk conversation repeatedly comes back to the same problem: sparse human data, uncertain purity and no consumer-grade way to verify what is in the vial.

Immune, inflammation and skin peptides

Thymosin alpha-1 is discussed for immune modulation, while KPV and LL-37 are discussed around inflammation, gut, wound and antimicrobial claims. These are not interchangeable supplements. FDA has flagged thymosin alpha-1, KPV and LL-37 in its peptide-risk materials, with concerns ranging from inadequate safety information to absent human exposure data and nonclinical warning signals.

GHK-Cu is a useful example of route mattering. Topical copper-peptide cosmetics are one conversation; injectable GHK-Cu is another. FDA specifically flags injectable GHK-Cu for immunogenicity and impurity concerns with limited human data. A skin-care ingredient does not become a safe injectable because the name is familiar.

Sex, tanning and cosmetic-adjacent peptides

Bremelanotide, also known from the PT-141 conversation, is FDA-approved as Vyleesi for a narrow indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Its label says it is not for men, not for postmenopausal women and not for enhancing sexual performance, and it has blood-pressure and cardiovascular cautions.

Melanotan II is a different risk profile. It is sold for tanning and libido in some gray markets, but FDA lists published case reports involving serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. This is not a harmless cosmetic shortcut.

The low-stakes exception: collagen peptides

Collagen peptides are popular too, but they belong in a different bucket. They are oral protein fragments sold as supplements, not injectable clinic protocols. The evidence is modest and outcome-specific, usually around skin hydration, elasticity or joint symptoms, and the downside profile is not comparable to unapproved injectables. Agewell may cover collagen separately, but it should not be mixed into the BPC-157 and retatrutide clinic conversation.

What Agewell will require before scoring this category

Before any peptide protocol can be recommended or scored here, the page needs more than testimonials. We would need a named clinician responsible for diagnosis and follow-up, jurisdiction-specific legality, a named licensed pharmacy or approved product, third-party quality controls where relevant, baseline and follow-up markers, exclusion criteria, adverse-event reporting and clear stop rules.

Until that bar is met, this page is informational only. It is not medical advice, not a protocol, not a dosage guide and not a substitute for a qualified clinician who can evaluate your actual medical history, medications, labs, contraindications and goals.

Sources

• FDAPeptide bulk substances and compounding safety-risk table, current as of April 22, 2026
• FDAHow Category 2 bulk substances are treated under 503A compounding policy
• LillyRetatrutide is investigational and not FDA-approved; legally available only in Lilly clinical trials
• LillyMay 2026 Phase 3 TRIUMPH-1 topline retatrutide results
• FDA labelWegovy semaglutide prescribing information and boxed warning
• FDAZepbound tirzepatide approval for chronic weight management
• FDA labelEgrifta tesamorelin prescribing information and limitations of use
• FDA labelVyleesi bremelanotide prescribing information and limitations of use
• WADAThe Prohibited List for substances and methods prohibited in sport